Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Venator Therapeutics Inc. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to a distinct examiner and is being reviewed within 1 distinct art unit. BEANE, RANDALL L is the busiest examiner for the portfolio, responsible for the 1 pending office action currently active.
The concentration of the workload into a single art unit and a single examiner means that the company's current prosecution success in Biotechnology & Pharmaceuticals is tied to this point of review. BEANE, RANDALL L handles the entirety of the company's current activity at the office. Practitioners should focus on this specific examiner's history, as there are no other active matters to provide a baseline for comparison within this portfolio.
With only a single pending matter, the administrative requirements are focused on a single front. The 1 distinct art unit involved will dictate the procedural norms for this case. Because the busiest examiner is the only one mentioned, their individual tendencies will be the primary factor in the prosecution of the current application in the Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BEANE, RANDALL L | 1 | 32.9% | +36.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18556019 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | BEANE, RANDALL L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18556019 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | BEANE, RANDALL L | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18556019 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | BEANE, RANDALL L | 1654 | §103§112Other | Non-Final OA | — | Pending | Oct 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVenator Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Randall L Beane has the most, with 1 of Venator Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
